SciSparc Announces Positive Topline Results For Proprietary Pain Management Compound In Pre-Clinical Study
August 2, 2021
Ryan Allway August 2nd, 2021 Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and Chronic Pain TEL AVIV, Israel, Aug. 2, 2021 /PRNewswire/ — SciSparc Ltd. (OTCQB: SPRCY) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160... Read more
Pharmadrug Announces Positive Research Results of Cepharanthine to Treat Multiple Cancers
July 28, 2021
Ryan Allway July 28th, 2021 Validates Cepharanthine’s potential in treating various cancers with unsatisfactory treatment options Positions Cepharanthine’s ‘pipeline in a pill’ strategy focusing on esophageal, colorectal, liver and skin cancers Advance to FDA IND-enabling studies to support human clinical studies Toronto, Ontario–(Newsfile Corp. – July 28, 2021) –... Read more
Innocan Pharma’s CBD Loaded Liposome Platform Technology Receives Positive Results from Recent Animal Study
CBD May 14, 2021
Ryan Allway May 14th, 2021 Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – May 14, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan“), is pleased to announce today that a recent study conducted in mice based on Innocan’s licensed CBD-loaded liposome platform technology... Read more
